Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Patients Who Have Previously Failed Interferon Therapy or Are Intolerant or Unable to Take Interferon

Inclusion Criteria:

1. Written informed consent must be obtained before any assessment is performed.

2. HCV G2/3 patients who have previously failed interferon therapy or are intolerant or
unable to take interferon.

3. Males or females aged ≥18 years.

4. Chronic hepatitis C virus infection diagnosed.

Exclusion criteria:

1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5
half-lives of that medication before enrollment.

2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical
classes

3. HBsAg positive

4. HIV positive.

Other protocol-defined inclusion/exclusion criteria apply.